Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 51

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 51
---
 on its
ability to expand its marketing and sales capabilities. NewGenIvf plans to continue expanding its direct sales force and to dedicate significant
resources to sales and marketing programs, including direct sales, inside sales, targeted direct marketing, advertising, digital marketing,
e-newsletter and conference sponsorships. All of these efforts will require it to invest significant financial and other resources. Its
business and results of operations could be harmed if its sales and marketing efforts do not generate significant increases in revenue.
NewGenIvf may not achieve anticipated revenue growth from expanding its sales and marketing efforts if it is unable to hire, develop,
integrate and retain talented and effective sales personnel, if its new and existing sales personnel, on the whole, are unable to achieve
desired productivity levels in a reasonable period of time, or if its sales and marketing programs are not effective.

NewGenIvf may experience net losses and may not sustain profitability in the future.

NewGenIvf experienced significant
revenue decrease from 2019 to 2020, due to the impact of COVID-19. NewGenIvf is not certain whether it will obtain sufficient levels of
sales to sustain its growth or maintain profitability in the future. NewGenIvf also expects its costs and expenses to increase in future
periods, which could negatively affect its future results of operations if its revenue does not increase accordingly. In particular, NewGenIvf
intends to continue to incrementally expand its sales and client account management teams to educate potential clients and drive new client
adoption. NewGenIvf also expects to incur additional costs as it introduces new solutions and services to enhance its comprehensive fertility
offering. NewGenIvf will also face increased compliance costs associated with growth, the expansion of its client base and being a public
company. NewGenIvf’s efforts to grow its business may be costlier than it expects, and NewGenIvf may not be able to increase its
revenue enough to offset its increased operating expenses. NewGenIvf may incur significant losses in the future for a number of reasons,
including the other risks described herein, and unforeseen expenses, difficulties, complications and delays, and other unknown events.
If NewGenIvf is unable to sustain profitability, the value of its business and common stock may significantly decrease.

NewGenIvf’s future revenue may not grow at the rates it historically has, or at all.

NewGenIvf has experienced
growth since its business operations started in 2014. Revenue